Lebrikizumab, An Anti-IL-13 Monoclonal Antibody, Reduces Severe Asthma Exacerbations Over 32 Weeks In Adults With Inadequately Controlled Asthma
暂无分享,去创建一个
S. Mosesova | M. Eisner | N. Hanania | J. Matthews | J. Corren | J. Arron | P. Lal | D. Mcclintock | Dana E. McClintock | Sofia Mosesova